Research from the University of North Carolina (UNC) School of Medicine indicates that popular weight loss and diabetes medications, such as semaglutide and tirzepatide, may lead to a concerning level of muscle loss in patients. Published in the Annals of Internal Medicine, the study, led by Professor John A. Batsis, an expert in obesity and nutrition, found that the proportion of muscle lost during weight loss on these drugs was significantly higher than anticipated. While some muscle loss is typical during weight reduction, the extent observed raised alarms among researchers. Professor Batsis emphasized the need for clinicians to pay closer attention to muscle health in patients using these medications. The study also pointed out a critical gap in research involving older adults, particularly those aged 65 and over, who are at higher risk for mobility issues and reduced quality of life due to muscle loss. The research team advocates for muscle evaluations to become standard in clinical trials and for new studies to focus on the effects of these medications in older populations.